Does Metformin Treatment during Pregnancy Modify the Future Metabolic Profile in Women with PCOS?

Autor: Marianne Andersen, Solhild Stridsklev, Maria Othelie Underdal, Kristin Høgetveit, Ingrid Hennum Oppen, Eszter Vanky
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Blood Glucose
endocrine system diseases
Endocrinology
Diabetes and Metabolism

Clinical Biochemistry
Blood Pressure
Biochemistry
Body Mass Index
Metformin/administration & dosage
0302 clinical medicine
Endocrinology
Pregnancy
Insulin
030219 obstetrics & reproductive medicine
Obstetrics
Polycystic Ovary Syndrome/blood
Lipids
Polycystic ovary
Metformin
Female
Waist Circumference
Polycystic Ovary Syndrome
medicine.drug
Adult
medicine.medical_specialty
030209 endocrinology & metabolism
Context (language use)
Placebo
Blood Pressure/drug effects
Waist Circumference/drug effects
03 medical and health sciences
Insulin resistance
Internal medicine
medicine
Hypoglycemic Agents
Humans
Lipids/blood
business.industry
Biochemistry (medical)
nutritional and metabolic diseases
Hypoglycemic Agents/administration & dosage
medicine.disease
Pregnancy Complications/blood
Pregnancy Complications
Pregnancy Trimester
First

Insulin Resistance
Metabolic syndrome
Insulin/blood
business
Insulin Resistance/physiology
Body mass index
Follow-Up Studies
Zdroj: Journal of Clinical Endocrinology and Metabolism
Underdal, M O, Stridsklev, S, Oppen, I H, Høgetveit, K, Andersen, M S & Vanky, E 2018, ' Does Metformin Treatment during Pregnancy Modify the Future Metabolic Profile in Women with PCOS? ', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 6, pp. 2408–2413 . https://doi.org/10.1210/jc.2018-00485
DOI: 10.1210/jc.2018-00485
Popis: Context Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS). Metformin may also benefit future health by modulating increased metabolic stress during pregnancy. Objective To investigate whether metformin during pregnancy modified future metabolic health in women with PCOS. Design Follow-up study of a randomized controlled trial that compared metformin with placebo in women with PCOS. Mean follow-up period was 7.7 years (range, 5 to 11 years). Setting Three university hospitals, seven local hospitals, and one gynecological specialist practice. Participants Women with PCOS according to Rotterdam criteria; all former participants in the Metformin in Pregnant PCOS Women Study. Intervention Metformin 2000 mg daily or placebo from first trimester to delivery in the original study. No intervention in the present follow-up study. Main Outcomes and Measures Main outcome measure was weight gain in the follow-up period. Weight, body mass index (BMI), waist and hip circumferences, and blood pressure (BP) were registered. Body composition was assessed by bioelectrical impedance analysis, and fasting lipids, glucose, and insulin were analyzed. Results Of 239 invited women, 131 (55%) participated in the follow-up. Weight gain was similar in women given metformin (2.1 ± 10.5 kg) and women given placebo (1.8 ± 11.2 kg) at 7.7 years’ follow-up after pregnancy (P = 0.834). No difference was found in BMI, waist/hip ratio, BP, body composition, lipids, glucose and insulin levels, or prevalence of metabolic syndrome at follow-up between those treated with metformin and those treated with placebo during pregnancy. Conclusion Metformin treatment during pregnancy did not influence the metabolic profile in women with PCOS at 7.7 years of follow-up. This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Clinical Endocrinology & Metabolism following peer review. The version of record is available online at: https://academic.oup.com/jcem/article/103/6/2408/4961064 and https://doi.org/10.1210/jc.2018-00485
Databáze: OpenAIRE